Alexion Pharm Inc (ALXN) Stock Price, Quote, News and Overview
NASDAQ:ALXN - Nasdaq -
ALXN Quote, Performance and Key Statistics
182.5
+3.05 (+1.7%)
The current stock price of ALXN is 182.5 null. In the past month the price increased by 1.02%. In the past year, price increased by 79.82%.
ALXN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ALXN
Company Profile
Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 3,837 full-time employees. The firm is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.
Company Info
Alexion Pharm Inc
121 Seaport Blvd
Boston MASSACHUSETTS 02210 US
CEO: Ludwig N. Hantson
Employees: 3837
Company Website: https://alexion.com/
Phone: 14752302596.0
Alexion Pharm Inc / ALXN FAQ
What is the stock price of Alexion Pharm Inc today?
The current stock price of ALXN is 182.5 null. The price increased by 1.7% in the last trading session.
What is the ticker symbol for Alexion Pharm Inc stock?
The exchange symbol of Alexion Pharm Inc is ALXN and it is listed on the Nasdaq exchange.
On which exchange is ALXN stock listed?
ALXN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Alexion Pharm Inc stock?
13 analysts have analysed ALXN and the average price target is 180.9 null. This implies a price decrease of -0.87% is expected in the next year compared to the current price of 182.5. Check the Alexion Pharm Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Alexion Pharm Inc worth?
Alexion Pharm Inc (ALXN) has a market capitalization of 40.34B null. This makes ALXN a Large Cap stock.
How many employees does Alexion Pharm Inc have?
Alexion Pharm Inc (ALXN) currently has 3837 employees.
What are the support and resistance levels for Alexion Pharm Inc (ALXN) stock?
Alexion Pharm Inc (ALXN) has a support level at 180.02 and a resistance level at 186.28. Check the full technical report for a detailed analysis of ALXN support and resistance levels.
Is Alexion Pharm Inc (ALXN) expected to grow?
The Revenue of Alexion Pharm Inc (ALXN) is expected to grow by 12.08% in the next year. Check the estimates tab for more information on the ALXN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Alexion Pharm Inc (ALXN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALXN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALXN, evaluating the profitability, health, valuation and growth aspects
- Alexion Pharm Inc (ALXN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Alexion Pharm Inc (ALXN) Sales and EPS estimates to see what analysts future expectations are.
- Alexion Pharm Inc (ALXN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Alexion Pharm Inc (ALXN) Insider and Institutional Ownership to learn about the owners and their transactions.
- Alexion Pharm Inc (ALXN) Stock Chart to make your own analysis
- Alexion Pharm Inc (ALXN) Latest news and press-releases to stay up to date.
Does Alexion Pharm Inc (ALXN) stock pay dividends?
ALXN does not pay a dividend.
When does Alexion Pharm Inc (ALXN) report earnings?
Alexion Pharm Inc (ALXN) will report earnings on 2022-02-22, before the market open.
What is the Price/Earnings (PE) ratio of Alexion Pharm Inc (ALXN)?
The PE ratio for Alexion Pharm Inc (ALXN) is 14.22. This is based on the reported non-GAAP earnings per share of 12.83 and the current share price of 182.5 null. Check the full fundamental report for a full analysis of the valuation metrics for ALXN.
ALXN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ALXN. When comparing the yearly performance of all stocks, ALXN is one of the better performing stocks in the market, outperforming 83.7% of all stocks.
ALXN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ALXN. ALXN has only an average score on both its financial health and profitability.
ALXN Financial Highlights
Over the last trailing twelve months ALXN reported a non-GAAP Earnings per Share(EPS) of 12.83. The EPS increased by 12.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.89% | ||
| ROA | 3.66% | ||
| ROE | 5.48% | ||
| Debt/Equity | 0.19 |
ALXN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 66% to ALXN. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 9.86% and a revenue growth 12.08% for ALXN